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Background/aim: To establish a regional screening protocol for retinopathy of prematurity (ROP).
Materials and methods: Data were analyzed from the hospital records of 1241 infants with gestational age (GA) at birth ≤36 weeks and
birth weight (BW) of ≤3600 g.
Results: The mean GA of the infants was 32.05 ± 2.7 weeks and the mean BW was 1780.5 ± 576 g. ROP at any stage was detected in 703
of the 1241 infants (555 female). Eleven infants with type 1 ROP were treated with 810 nm diode laser photocoagulation. No treatment
was needed in infants born after 33 weeks of gestation and weighing over 1760 g. Logistic regression analysis showed a significant
relationship between the development of ROP and GA, BW, number of deliveries, respiratory distress syndrome, and treatment with
oxygen or mechanical ventilation. Receiver operating characteristic curve analysis showed that a GA of 33 weeks or a BW of 1770 g
appears to be an appropriate criterion for identifying infants who may require ROP treatment.
Conclusion: GA ≤ 33 weeks and BW ≤ 1770 g can be used as screening criteria in terms of ROP in infants for the Eastern Black Sea
region.
Key words: Premature birth, neonatal screening, retinopathy of prematurity

1. Introduction
The retinal vessels mainly develop in two periods in
embryological life. The major retinal vessels develop
between 14 and 21 weeks, known as the vasculogenesis
phase, while vascularization of other retinal regions
continues until the 40th week of gestational age (GA),
known as the angiogenesis phase (1). Retinopathy of
prematurity (ROP) develops in infants born prematurely,
in association with lack of development of retinal vessels,
and is an increasingly important cause of blindness in
children, particularly in middle-income countries of Asia
and other countries around the world (2–7). Although the
major risk factors for the development of ROP are preterm
labor and low birth weight (BW), other risk factors include
excess oxygen, sepsis, asphyxia, blood exchange, and
respiratory distress syndrome (RDS) (8–12).
Regular screening for and early detection and treatment
of ROP are essential in preventing blindness in premature
newborns. Screening and treatment should be performed
on the basis of blood vessel development and the stage of
ROP (13–15). Infants born before 30 weeks and weighing
* Correspondence: doktorademturk@yahoo.com

less than 1500 g in the United States, and before 32 weeks
and under 1500 g in the United Kingdom, are usually
considered to be at high risk for ROP. However, it has been
recommended that developing countries should define
screening criteria on the basis of their own particular
conditions. Infants requiring treatment for ROP may be
overlooked if screening is performed according to limits
defined by developed countries (5,16–18).
The purpose of this study was to document data from
a major center in the Eastern Black Sea region of Turkey
and to help establish a regional screening protocol for ROP
for the Eastern Black Sea region of Turkey. Another aim
was to determine the incidence, risk factors, and clinical
characteristics of infants with ROP in this region.
2. Materials and methods
This study was performed as a retrospective review of
medical records. Premature infants were examined for
ROP between January 2010 and December 2011 at the
Department of Ophthalmology, Faculty of Medicine,
Karadeniz Technical University, Turkey. A total of 1648
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premature babies examined at less than 36 weeks were
evaluated since there are no disease-specific screening
criteria for ROP in Turkey. The infants were either born at
the medical faculty hospital or elsewhere, and were referred
from other hospitals. Infants with ocular abnormalities
or those who were unable to attend follow-up visits were
excluded from the study. The study was designed not
according to 2013 guideline criteria but on the basis of
previous criteria recognized in the United States at the time
of the study (19). The first examination was performed at
31 weeks of GA or at 4 weeks after birth, whichever came
earlier. The follow-up examinations were repeated at 3-day
or 3-week intervals, depending on the severity of the retinal
findings, and continued until complete vascularization or
progression to type I ROP requiring laser therapy. Type I
ROP includes: Zone I, any stage with plus disease; Zone I,
stage 3 without plus disease; and Zone II, stage 2–3 with
plus disease (20). Informed consent for examination and
treatment, if necessary, was obtained from the families.
All premature babies born in the Eastern Black Sea
region have to undergo eye screening. At the time of
preparation of the manuscript, our hospital was the
only center in the region (the Eastern Black Sea region
of Turkey) where premature babies were referred for
examination. Therefore, we think that our examination
results may sufficiently reflect the population of the region.
Our hospital is still the only center in our region where
ROP treatment is available. The physicians (HE, MK)
performing ROP examinations have been doing this in the
region for approximately 20 years.
A mixture of phenylephrine 2.5% and tropicamide
1% drops was administered 3 times at 5-min intervals in
all infants before examination. Fundus examination was
performed with a binocular indirect ophthalmoscope
using both +20 D and +28 D lenses, a lid speculum, and
a scleral depressor approximately 45 min after the first
instillation. Topical anesthetic (0.5% proparacaine) was
used for the examination and no other drug was given
for sedation. At ophthalmological examination, dilation
of the pupils, features of the lens, optic nerve, and retinal
vascularization (location, stage, and absence or presence
of plus disease) were assessed and recorded. BW, GA,
duration of oxygen therapy, blood transfusion, asphyxia,
RDS and sepsis, and number of births (single or twin) were
recorded. All examinations were recorded as video files.
ROP classification was performed according to the revised
International Classification of ROP, including the extent,
zone, and presence or absence of plus disease (13,15).
All infants in the high-risk ROP group were monitored
on the basis of ETROP (20) and CRYOROP (21) criteria.
Eleven infants requiring treatment on the basis of ETROP
(20) were treated with an 810 nm wavelength diode laser
(IRIDEX, Mountain View, CA, USA). Laser treatment
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was performed under ketamine (0.5–1 mg/kg) anesthesia.
Infants were followed up until ROP regressed after laser
treatment. Examinations and treatments were performed
by two authors (HE, MK) under anesthesiologist
supervision in the operating room.
Infants were divided into two subgroups as appropriate
for the screening criteria for ROP in the United States.
Group I included infants with GA ≤ 32 weeks and infants
with BW ≤ 1500 g. Group II includes infants with GA >
32 weeks and infants with BW > 1500 g. These subgroups
were then compared with each other. In addition, infants
with ROP requiring treatment were also compared with
those not requiring treatment.
SPSS (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. Descriptive data were presented as
means ± SD. Student’s t test was used for quantitative
comparisons, and a chi-square test for qualitative
comparisons. Correlations between GA, BW, number of
deliveries, RDS, and treatment with oxygen or mechanical
ventilation (MV) and ROP were evaluated using stepwise
multivariate logistic regression analysis. P < 0.05 was
considered significant. ROC curve analysis for BW and
GA was performed to determine screening criteria for
ROP for our region, since these are usually considered the
best predictors for ROP.
3. Results
We initially reviewed the records of 1648 babies; 1241
babies whose records were complete were finally included
in the study and followed up regularly. The mean GA of the
infants was 32.05 ± 2.7 (24–36) weeks and the mean BW
was 1780.5 ± 576 (620–3600) g. Five hundred and fiftyfive infants (44.8%) were female and 686 (55.2%) were
male. Eight hundred and eighty-seven infants (71.5%) had
spent more than 7 days in the incubator, and 134 babies
(7.7%) had undergone MV. RDS developed in 342 infants
(27.55%). Of all infants, 184 (14.8%) were twins, 660
(53.2%) were born at 32 weeks or below, and 581 (46.8%)
were born after 32 weeks. Four hundred and fifty-five
babies (36.7%) weighed 1500 g or less and 786 (63.3%)
babies weighed over 1500 g.
ROP at any stage was seen in 703 infants (56.7%). Of
the infants with ROP, 647 (92.03%) had stage 1, 38 (5.40%)
had stage 2, and 18 (2.56%) had stage 3 findings. Eight
(1.1%) infants had zone 1 ROP, 126 (17.9%) had zone 2
ROP, and 569 (80.9%) had zone 3 ROP. During followup, type 1 ROP was observed in 11 (0.9%) infants; they
received laser treatment using an 810 nm diode laser
(IRIDEX) to the avascular retina. Eight of the 11 infants
in the study required bilateral treatment and 3 required
unilateral treatment. Since we wished to emphasize only
babies requiring treatment, the number of babies was
cited instead of the number of eyes. Ten infants exhibited
regression, and only one received surgical treatment.
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Significant differences were determined between
infants with and without ROP in terms of mean GA,
BW, rate of oxygen therapy, rate of MV use, number of
pregnancies, and rate of RDS (Table 1).
In the evaluation of subgroups, ROP at any stage was
observed in 302 infants (75.8%) in Group I and in 207
infants (39.5%) in Group II. However, the majority of
infants [205 cases (99.1%)] in Group II had stage 1 ROP
or immature retina. Only 2 infants in Group II had stage
2 ROP. No stage 3 ROP was detected and only 1 (0.4%)
infant required treatment. In terms of GA alone, 239
infants (41.1%) with GA above 32 weeks and 369 (46.9%)
infants weighing more than 1500 g had any stage of ROP.

Table 2 shows the rates of ROP on the basis of subgroups
and statistical results.
When comparing infants with type I ROP and infants
with any stage ROP except type I, there was no significant
difference in terms of sex or number of pregnancies (P =
0.889 and 0.465, respectively). On the other hand, there
were significant differences in GA (28.49 ± 2.04 vs. 31.67
± 2.59 weeks), BW (1178.8 ± 310.7 vs. 1669.3 ± 499.7 g),
oxygen therapy time (30.76 ± 16.78 vs. 18.2 ± 15.15 days),
mechanical ventilation time (9.17 ± 4.87 vs. 4.9 ± 6.92
days), and RDS rate (9 vs. 194) between infants with type
I ROP and the other infants with ROP (P = 0.001, 0.001,
0.003, 0.02, and 0.001, respectively).

Table 1. General characteristics of infants with or without ROP.
All infants
(n = 1241)

ROP (+)
(n = 703)

ROP (–)
(n = 538)

P level

Gestational age (week)

32.05 ± 2.7

31.34 ± 2.71

32.98 ± 2.47

0.001

Birth weight (g)

1780.5 ± 576

1618 ± 506

1992 ± 593

0.004

Male

686

382

304

0.6

Female

555

321

234

Oxygen therapy more than 7 days (n)

887

635

252

0.001

Mechanical ventilation (n)

134

117

27

0.001

Respiratory distress syndrome (n)

342

203

139

0.008

Single pregnancy (n)

1057

582

475

0.08

Twin pregnancy (n)

184

121

63

Sex (n)

Table 2. Distribution of ROP and its stages in infants on the basis of gestational age and birth weight.
Stages of ROP

n

ROP (+)
(n =703) (%)

ROP (–)
(n = 538) (%)

1

2

3

Required
treatment

Group I

398

302 (75.8%)

96 (24.1%)

267

25

10

7

Group II

524

207 (39.5%)

317 (60.5%)

205

2

-

1

0.001

0.001

-

0.001

P level

0.001

Only GA
≤32 w

660

464 (70.3%)

196 (29.7%)

411

35

18

10

>32 w

581

239 (41.1%)

342 (58.8%)

236

3

-

1

0.001

0.006

-

0.001

P level

0.001

Only BW
≤1500 g

455

334 (73.4%)

121 (26.5%)

298

26

10

8

>1500 g

786

369 (46.9%)

417 (53.0%)

349

12

8

3

0.008

0.007

0.501

0.001

P level

0.001
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The results of logistic regression analysis investigating
the relationships between risk factors and ROP are shown
in Table 3. These findings show a significant positive
relationship between the development of ROP and the
number of deliveries, RDS, oxygen treatment, and use
of MV, and a negative relationship of ROP development
with GA and BW. Table 3 shows that BW, GA, duration of
mechanical ventilation and oxygen therapy, and presence
of RDS increased the risk for ROP development more than
twofold.
Since two of the major parameters for ROP screening
were BW and GA, ROC analysis was performed to define
the screening criteria for ROP in infants born in the
Eastern Black Sea region of Turkey. The ROP score was
AUC = 0.683 (sensitivity: 64.86 and specificity: 64.5, P <
0.001) for predicting any stage of ROP in terms of BW; the
BW cut-off value was ≤1770 g (Figure 1; Table 4).
Birth weight
100

Sensitivity

80

Sensitivity: 64.9
Specificity: 64.5
Criterion : 1770

60

40

20
AUC = 0.683
P < 0.001

0
0

20

40
60
100-Specificity

80

100

Figure 1. ROC analysis according to birth weight for determining
ROP treatment requirement in premature infants.

The ROP score was AUC = 0.678 (sensitivity: 76.67
and specificity: 51.86, P < 0.001) for predicting any stage
ROP in terms of GA; the GA cut-off value was ≤33 weeks
(Figure 2; Table 5).
4. Discussion
The number of premature births has increased
approximately 30% in the last 25 years (22,23). Parallel
to this increase, the number of babies with ROP is also
rising. This is an important retinal vascular disease leading
to blindness in extremely premature infants. These babies
should therefore be screened periodically and treated
at the appropriate time. Significant risk factors for the
development of ROP include GA, BW, presence of RDS,
presence of sepsis, a history of blood transfusion, and
duration of mechanical ventilation and oxygen therapy
(8–10). The two most important risk factors for the
development of ROP are BW and GA, and these factors
are taken into account when screening babies. Screening
criteria have been established for the early detection of
ROP and for babies in risk groups in the United States and
the United Kingdom. These criteria are weight under 1500
g and birth earlier than 30 weeks in the United States, and
weight under 1500 g and birth earlier than 31 weeks in
the United Kingdom (16,24). Infants with GA > 32 weeks
or BW > 1500 g are not usually screened in developed
countries.
The incidence of ROP differs by countries, regions,
races, and even intensive care units (5,12,25). Although
screening criteria for ROP have been defined in developed
countries, it has been reported that some babies requiring
treatment for ROP will still be overlooked if these criteria
are also adopted for screening in developing countries
(3,12,18,25–29). In a study performed in an intensive care
unit in Taiwan, evidence of ROP requiring treatment was
encountered in infants weighing up to 2000 g, and stage 3
ROP was identified in 2.6% of the babies born later than 30
weeks, although none required treatment (30). In a study
conducted in Iran, the authors observed a rate of ROP of
18.3% in infants born after than 32 weeks, and plus disease

Table 3. Logistic regression analysis results for ROP risk parameters.
Odds ratio

CI

P level

Gestational age

2.58

1.96–3.38

0.001

Birth weight

2.10

1.56–2.81

0.001

Number of births

1.80

1.23–2.63

0.016

Respiratory distress syndrome

2.86

2.05–4.27

0.001

Oxygen therapy

2.07

1.27–2.76

0.025

Mechanical ventilation

2.54

1.82–3.47

0.007
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Table 4. ROC analysis results according to birth weight for determining ROP treatment requirement in premature infants.
Birth weight (g)

Sensitivity

95% CI

Specificity

95% CI

1750

63.73

60.0–67.3

64.87

60.7–68.9

1760

64.44

60.8–68.0

64.68

60.5–68.7

1770

64.86

61.2–68.4

64.50

60.3–68.5

1780

65.01

61.4–68.5

64.13

59.9–68.2

1790

65.15

61.5–68.7

63.75

59.5–67.8

1800

68.28

64.7–71.7

57.99

53.7–62.2

Gestational age
100

80

Sensitivity

Sensitivity: 76.7
Specificity: 51.9
Criterion : 33
60

40

20
AUC = 0.678
P < 0.001
0
0

20

40
60
100-Specificity

80

100

Figure 2. ROC analysis results according to gestational age for
determining ROP treatment requirement in premature infants.

was determined in 2.7% of babies born after 32 weeks
(25). Binkhathlan et al. (31) reported that the sensitivity
of ROP screening increases from 68% to 93% when the
screening protocol was changed to involve babies with GA
< 34 weeks and BW < 1800 g. Another study, from China,
reported that screening criteria vary according to intensive
care units and recommended that each region develop its
own screening criteria in light of its own characteristics
(12). Gilbert et al. (5) emphasized that ROP is seen more
in term infants in low- and medium-developed countries
than in infants in developed countries, and suggested that
such countries should establish their own local screening
criteria.
There are socioeconomic and cultural differences
among the various regions of Turkey. One aim of our study

was to determine whether this affects the incidence of ROP
and to reveal whether the incidence differs among regions.
Studies intended to determine screening criteria for the
weight and the age limit of infants requiring treatment in
Turkey have also stated that the criteria they propose may
vary from region to region. The incidence of ROP in infants
with GA greater than 32 weeks has been reported as 9.3%
and 11.1% in two different studies from Turkey (18,32).
The incidence was calculated as 41.1% in our study. This
level, being higher than those in other studies, may be due
to the screening for ROP, which is still compulsory, not
being fully implemented in our region; only premature
infants with high risk factors are being referred to us for
ROP screening. Other reasons for our results differing
from those of previous studies may include regional
variations in socioeconomic status, level of development in
neonatal care units, and infant monitoring strategies. Our
results also show that the risk of ROP in infants with GA
greater than 32 weeks is higher in our region than that in
developed countries. Infants with ROP may, therefore, be
overlooked in screening if data from developed countries
are adopted as screening criteria in our region. Studies
conducted in order to determine screening criteria for
ROP in Turkey have suggested that preterm babies with
GA < 34 weeks and BW < 1850 g should be included in
the screening (27,33). In another study, the level of ROP in
infants born after 33 weeks was reported at 17.8%, and that
of ROP in infants born weighing more than 2000 g was
13.1%. Screening criteria for ROP of 2000 g and 34 weeks
have been suggested for Turkey (34).
In our study, of the 524 babies in Group II, 207 (39.5%)
had ROP at any stage. Of these infants, 205 (99%) had
stage 1 and 2 infants were stage 2 ROP. However, only
1 infant (0.5%) in this group needed treatment in the
follow-up period. Based on the data obtained from infants
we examined and followed, and on the results of receiver
operating characteristic (ROC) analysis performed to
determine the limits of ROP screening, infants with GA
≤ 33 weeks and with BW ≤ 1770 g should be included in
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Table 5. ROC analysis results according to gestational age for determining ROP treatment requirement in premature infants.
Gestational age (weeks)

Sensitivity

95% CI

Specificity

95% CI

30

35.85

32.3–39.5

83.83

80.4–86.8

31

46.37

42.6–50.1

77.88

74.1–81.3

32

66.00

62.4–69.5

63.57

59.3–67.6

33

76.67

73.4–79.8

51.86

47.5–56.2

34

86.20

83.4–88.7

28.62

24.8–32.6

the screening criteria in the Eastern Black Sea region of
Turkey. When we evaluated 338 infants not meeting the
screening criteria (>33 weeks and >1770 g), 121 (35.8%)
had ROP at any stage, but all of these findings regressed
and did not require any treatment. These findings also
suggest that our proposed screening criteria are reliable for
ROP in this region. On the basis of these results, the cutoff values for ROP screening of 33 weeks and 1770 g will
be suitable for identifying infants requiring ROP therapy
in the Eastern Black Sea region of Turkey. One study from
the Western Black Sea region of Turkey reported GA ≤ 32
weeks or a BW ≤ 1900 g to be a suitable screening criterion
(18). Another study from the Central Black Sea region of
Turkey recommended GA of <34 weeks and BW of <1800
g for screening criteria (27).

The facts that other risk factors, such as sepsis and
blood transfusion, that might affect development of ROP
were not included, and that the research was performed
retrospectively, represent limitations of the present study.
In conclusion, low GA, low BW, multiple pregnancies,
presence of RDS, and treatment with oxygen or a history
of MV have been identified as regional risk factors for
development of ROP in infants in the Eastern Black Sea
region of Turkey. GA of ≤33 weeks and BW of ≤1770 g
were significant as screening criteria in premature infants
in the region. However, comorbidity of these risk factors
may necessitate examination of infants outside these
margins.
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